Sino Biopharmaceutical Limited Sino Biopharmaceutical Limited

Sino Biopharmaceutical Limited

1177

Classificação em ações #1744
Sino Biopharmaceutical Limited, an investment holding company, operates as a... Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Preço da ação
$0.68696386
Valor de mercado
$12.23B
Variação (1 dia)
2.29%
Variação (1 ano)
-28.18%
País
HK
Negociar Sino Biopharmaceutical Limited (1177)

Categoria

Healthcare
Histórico de dividendos de Sino Biopharmaceutical Limited (1177)
Sino Biopharmaceutical Limited (símbolo da ação: 1177) realizou um total de 69 pagamentos de dividendos.
A soma de todos os dividendos (ajustada para desdobramentos de ações) é: $0.70
Rendimento de dividendos (TTM): 0.0229
Pagamentos de dividendos de Sino Biopharmaceutical Limited (1177) de 2004 a 2026
Pagamentos anuais de dividendos
Ano Dividendo (ajustado para desdobramentos) Alterar
2026 (TTM) $0.05 -44.44%
2025 $0.09 50.00%
2024 $0.06 -25.00%
2023 $0.08 -20.00%
2022 $0.1 150.00%
2021 $0.04 -24.95%
2020 $0.0533 33.58%
2019 $0.0399 12.39%
2018 $0.0355 13.78%
2017 $0.0312 55.22%
2016 $0.0201 128.41%
2015 $0.0088 -53.93%
2014 $0.0191 28.19%
2013 $0.0149 24.17%
2012 $0.012 -49.15%
2011 $0.0236 0.00%
2010 $0.0236 214.67%
2009 $0.0075 19.05%
2008 $0.0063 -25.88%
2007 $0.0085 26.87%
2006 $0.0067 -59.64%
2005 $0.0166 730.00%
2004 $0.002 0.00%
Lista de todos os pagamentos de dividendos
Ano Dividendo Alterar
2026 (TTM) $0.05 -44.44%
2025 $0.09 50.00%
2024 $0.06 -25.00%
2023 $0.08 -20.00%
2022 $0.1 150.00%
2021 $0.04 -33.33%
2020 $0.06 0.00%
2019 $0.06 12.57%
2018 $0.0533 -23.86%
2017 $0.07 55.56%
2016 $0.045 50.00%
2015 $0.03 -53.85%
2014 $0.065 30.00%
2013 $0.05 25.00%
2012 $0.04 -50.00%
2011 $0.08 0.00%
2010 $0.08 77.78%
2009 $0.045 3.93%
2008 $0.0433 -27.83%
2007 $0.06 33.33%
2006 $0.045 -64.00%
2005 $0.125 525.00%
2004 $0.02 0.00%
Dividendos de empresas semelhantes ou concorrentes